Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neutrophils | 87 | 2022 | 1233 | 10.660 |
Why?
|
Blood Coagulation Disorders | 42 | 2023 | 208 | 10.470 |
Why?
|
Fibrinolysis | 32 | 2023 | 159 | 9.770 |
Why?
|
Wounds and Injuries | 71 | 2023 | 772 | 9.490 |
Why?
|
Shock, Hemorrhagic | 46 | 2023 | 206 | 7.850 |
Why?
|
Acute Lung Injury | 31 | 2018 | 310 | 6.440 |
Why?
|
Thrombelastography | 50 | 2023 | 192 | 5.790 |
Why?
|
Plasma | 30 | 2022 | 224 | 5.710 |
Why?
|
Transfusion Reaction | 29 | 2021 | 79 | 5.670 |
Why?
|
Tissue Plasminogen Activator | 19 | 2023 | 231 | 5.500 |
Why?
|
Blood Preservation | 32 | 2021 | 311 | 4.960 |
Why?
|
Erythrocyte Transfusion | 28 | 2022 | 210 | 4.260 |
Why?
|
Blood Component Transfusion | 15 | 2020 | 84 | 4.230 |
Why?
|
Resuscitation | 31 | 2023 | 253 | 4.150 |
Why?
|
Blood Platelets | 25 | 2022 | 369 | 4.010 |
Why?
|
Erythrocytes | 22 | 2022 | 641 | 3.730 |
Why?
|
Neutrophil Activation | 17 | 2018 | 100 | 3.290 |
Why?
|
Blood Transfusion | 27 | 2022 | 306 | 2.950 |
Why?
|
Multiple Organ Failure | 30 | 2023 | 150 | 2.930 |
Why?
|
Blood Coagulation | 17 | 2023 | 219 | 2.880 |
Why?
|
Thrombin | 10 | 2023 | 143 | 2.680 |
Why?
|
Hemorrhage | 16 | 2023 | 623 | 2.520 |
Why?
|
Platelet Activating Factor | 21 | 2019 | 95 | 2.410 |
Why?
|
Plasminogen Activator Inhibitor 1 | 8 | 2023 | 82 | 2.410 |
Why?
|
Saline Solution, Hypertonic | 14 | 2019 | 56 | 2.220 |
Why?
|
Fibrinogen | 11 | 2023 | 161 | 2.140 |
Why?
|
Lysophosphatidylcholines | 10 | 2016 | 36 | 2.130 |
Why?
|
Thrombophilia | 6 | 2023 | 68 | 1.860 |
Why?
|
Proteomics | 21 | 2023 | 876 | 1.770 |
Why?
|
NADPH Oxidases | 15 | 2016 | 138 | 1.730 |
Why?
|
Lipids | 12 | 2017 | 607 | 1.690 |
Why?
|
Lung | 24 | 2023 | 3664 | 1.680 |
Why?
|
Humans | 242 | 2023 | 118974 | 1.620 |
Why?
|
Fibrinolysin | 4 | 2023 | 17 | 1.610 |
Why?
|
Antifibrinolytic Agents | 7 | 2023 | 44 | 1.600 |
Why?
|
Receptors, G-Protein-Coupled | 8 | 2012 | 200 | 1.560 |
Why?
|
Lymph | 9 | 2016 | 40 | 1.550 |
Why?
|
Rats | 35 | 2023 | 5392 | 1.540 |
Why?
|
Superoxides | 24 | 2011 | 221 | 1.510 |
Why?
|
Fibrinolytic Agents | 4 | 2022 | 238 | 1.500 |
Why?
|
Thrombosis | 6 | 2023 | 309 | 1.430 |
Why?
|
Antibodies | 7 | 2016 | 392 | 1.390 |
Why?
|
Blood Proteins | 8 | 2018 | 248 | 1.390 |
Why?
|
Endothelial Cells | 8 | 2023 | 732 | 1.360 |
Why?
|
Cell Membrane | 8 | 2016 | 710 | 1.340 |
Why?
|
Platelet Transfusion | 9 | 2023 | 68 | 1.320 |
Why?
|
Rats, Sprague-Dawley | 34 | 2019 | 2478 | 1.320 |
Why?
|
Male | 130 | 2023 | 57801 | 1.280 |
Why?
|
Leukocyte Reduction Procedures | 3 | 2018 | 28 | 1.260 |
Why?
|
Leukocyte Elastase | 9 | 2017 | 80 | 1.240 |
Why?
|
Transfusion-Related Acute Lung Injury | 4 | 2019 | 6 | 1.230 |
Why?
|
Protein Kinase C | 3 | 2017 | 297 | 1.210 |
Why?
|
Hemoglobins | 7 | 2022 | 326 | 1.200 |
Why?
|
Calcium | 17 | 2023 | 1169 | 1.180 |
Why?
|
Injury Severity Score | 25 | 2023 | 528 | 1.170 |
Why?
|
Blood Substitutes | 5 | 2015 | 28 | 1.160 |
Why?
|
Tranexamic Acid | 5 | 2020 | 37 | 1.120 |
Why?
|
Multiple Trauma | 9 | 2023 | 97 | 1.110 |
Why?
|
Platelet Aggregation | 4 | 2022 | 97 | 1.100 |
Why?
|
Endothelium, Vascular | 13 | 2022 | 907 | 1.090 |
Why?
|
Mitogen-Activated Protein Kinases | 9 | 2003 | 298 | 1.070 |
Why?
|
Adult | 79 | 2023 | 31512 | 1.060 |
Why?
|
Plasminogen | 4 | 2023 | 34 | 1.040 |
Why?
|
Animals | 75 | 2023 | 33381 | 1.020 |
Why?
|
Disease Models, Animal | 27 | 2023 | 3730 | 1.000 |
Why?
|
ABO Blood-Group System | 3 | 2022 | 35 | 0.980 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 10 | 2013 | 285 | 0.970 |
Why?
|
Mesentery | 12 | 2015 | 56 | 0.960 |
Why?
|
beta-Globins | 2 | 2022 | 16 | 0.960 |
Why?
|
Pancreatic Elastase | 11 | 2016 | 74 | 0.940 |
Why?
|
Carboxypeptidase B2 | 1 | 2023 | 4 | 0.910 |
Why?
|
Arachidonic Acid | 4 | 2022 | 122 | 0.910 |
Why?
|
Bradykinin | 1 | 2023 | 48 | 0.910 |
Why?
|
Lung Injury | 6 | 2016 | 210 | 0.900 |
Why?
|
Uterine Inertia | 1 | 2022 | 2 | 0.900 |
Why?
|
Female | 96 | 2023 | 61565 | 0.900 |
Why?
|
Respiratory Burst | 12 | 2016 | 31 | 0.900 |
Why?
|
Intercellular Adhesion Molecule-1 | 7 | 2015 | 175 | 0.890 |
Why?
|
Postpartum Hemorrhage | 1 | 2022 | 16 | 0.880 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2006 | 204 | 0.880 |
Why?
|
Lung Diseases | 8 | 2008 | 718 | 0.870 |
Why?
|
Cytokines | 11 | 2021 | 1900 | 0.860 |
Why?
|
Enzyme Activation | 14 | 2017 | 828 | 0.860 |
Why?
|
Sodium Chloride | 4 | 2018 | 144 | 0.790 |
Why?
|
Oxidoreductases | 3 | 2011 | 100 | 0.790 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2020 | 9 | 0.780 |
Why?
|
Tumor Necrosis Factor-alpha | 9 | 2014 | 1171 | 0.780 |
Why?
|
Brain Injuries, Traumatic | 6 | 2023 | 318 | 0.780 |
Why?
|
alpha-2-Antiplasmin | 1 | 2020 | 3 | 0.770 |
Why?
|
Blood Component Removal | 3 | 2021 | 34 | 0.770 |
Why?
|
Phosphoproteins | 5 | 2009 | 308 | 0.760 |
Why?
|
Macrophage-1 Antigen | 8 | 2002 | 36 | 0.750 |
Why?
|
Inflammation | 16 | 2023 | 2566 | 0.740 |
Why?
|
In Vitro Techniques | 12 | 2020 | 1094 | 0.730 |
Why?
|
Receptors, Leukotriene B4 | 2 | 2017 | 10 | 0.730 |
Why?
|
Clathrin | 3 | 2010 | 31 | 0.730 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 13 | 2008 | 67 | 0.730 |
Why?
|
Inflammation Mediators | 3 | 2013 | 502 | 0.720 |
Why?
|
Interleukin-8 | 8 | 2013 | 249 | 0.700 |
Why?
|
Platelet Membrane Glycoproteins | 6 | 2009 | 43 | 0.700 |
Why?
|
Hemolysis | 3 | 2022 | 174 | 0.690 |
Why?
|
Blood Transfusion, Autologous | 3 | 2011 | 22 | 0.690 |
Why?
|
Succinic Acid | 5 | 2020 | 46 | 0.690 |
Why?
|
Leukapheresis | 4 | 2011 | 27 | 0.680 |
Why?
|
Proto-Oncogene Proteins c-hck | 2 | 2016 | 5 | 0.680 |
Why?
|
Metabolome | 6 | 2018 | 296 | 0.680 |
Why?
|
MAP Kinase Signaling System | 4 | 2008 | 292 | 0.670 |
Why?
|
Healthy Volunteers | 6 | 2020 | 201 | 0.670 |
Why?
|
Point-of-Care Systems | 5 | 2021 | 151 | 0.670 |
Why?
|
Wounds, Nonpenetrating | 6 | 2023 | 285 | 0.660 |
Why?
|
Cytoplasmic Granules | 1 | 2018 | 84 | 0.660 |
Why?
|
Leukotriene B4 | 6 | 2011 | 51 | 0.660 |
Why?
|
Balloon Occlusion | 3 | 2023 | 26 | 0.660 |
Why?
|
Middle Aged | 50 | 2023 | 27617 | 0.640 |
Why?
|
Filtration | 2 | 2018 | 64 | 0.640 |
Why?
|
Cytosol | 7 | 2010 | 221 | 0.630 |
Why?
|
Phospholipases A | 6 | 2002 | 101 | 0.630 |
Why?
|
Platelet Function Tests | 3 | 2019 | 25 | 0.630 |
Why?
|
Refrigeration | 1 | 2017 | 11 | 0.610 |
Why?
|
Isoantibodies | 5 | 2018 | 63 | 0.600 |
Why?
|
Cell Cycle Proteins | 2 | 2012 | 565 | 0.600 |
Why?
|
Metabolomics | 8 | 2023 | 550 | 0.600 |
Why?
|
Pulmonary Edema | 6 | 2019 | 125 | 0.600 |
Why?
|
Osmolar Concentration | 4 | 2013 | 185 | 0.600 |
Why?
|
Sex Characteristics | 4 | 2022 | 671 | 0.600 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2014 | 30 | 0.590 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 7 | 2018 | 827 | 0.590 |
Why?
|
Prospective Studies | 20 | 2022 | 6471 | 0.590 |
Why?
|
Time Factors | 25 | 2019 | 6412 | 0.590 |
Why?
|
Pancreatic Neoplasms | 7 | 2013 | 734 | 0.590 |
Why?
|
Endocytosis | 2 | 2009 | 156 | 0.580 |
Why?
|
Microvessels | 2 | 2017 | 77 | 0.570 |
Why?
|
Blood Donors | 5 | 2014 | 109 | 0.570 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2016 | 355 | 0.570 |
Why?
|
Blood Coagulation Tests | 6 | 2023 | 58 | 0.560 |
Why?
|
Adenosine Diphosphate | 5 | 2022 | 88 | 0.550 |
Why?
|
Protein Kinase C-delta | 1 | 2016 | 69 | 0.550 |
Why?
|
Microcirculation | 2 | 2017 | 155 | 0.540 |
Why?
|
Receptor, PAR-2 | 1 | 2015 | 8 | 0.540 |
Why?
|
Systemic Inflammatory Response Syndrome | 4 | 2015 | 75 | 0.540 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2015 | 34 | 0.540 |
Why?
|
Models, Immunological | 2 | 2013 | 94 | 0.530 |
Why?
|
Lymphatic System | 3 | 2004 | 13 | 0.530 |
Why?
|
Interleukin-18 | 2 | 2009 | 228 | 0.510 |
Why?
|
Trauma Centers | 12 | 2021 | 388 | 0.510 |
Why?
|
Thrombolytic Therapy | 1 | 2015 | 118 | 0.500 |
Why?
|
Protein Kinases | 3 | 2010 | 310 | 0.500 |
Why?
|
Leukocytes, Mononuclear | 3 | 2014 | 509 | 0.500 |
Why?
|
Phosphorylation | 10 | 2016 | 1633 | 0.490 |
Why?
|
Plateletpheresis | 3 | 2018 | 28 | 0.490 |
Why?
|
Hemoglobins, Abnormal | 1 | 2014 | 10 | 0.490 |
Why?
|
Hemostasis | 3 | 2023 | 70 | 0.480 |
Why?
|
Hemoglobinopathies | 1 | 2014 | 6 | 0.480 |
Why?
|
Mass Spectrometry | 11 | 2018 | 681 | 0.480 |
Why?
|
HLA-A2 Antigen | 1 | 2013 | 39 | 0.480 |
Why?
|
Abdominal Injuries | 1 | 2015 | 119 | 0.470 |
Why?
|
Cells, Cultured | 14 | 2018 | 4077 | 0.470 |
Why?
|
Lipid Metabolism | 1 | 2017 | 477 | 0.470 |
Why?
|
Liver | 3 | 2018 | 1816 | 0.460 |
Why?
|
CD18 Antigens | 8 | 2008 | 35 | 0.460 |
Why?
|
Cell-Derived Microparticles | 1 | 2014 | 62 | 0.460 |
Why?
|
Proteome | 3 | 2023 | 353 | 0.450 |
Why?
|
Apoptosis | 7 | 2014 | 2484 | 0.450 |
Why?
|
Anticoagulants | 4 | 2023 | 559 | 0.440 |
Why?
|
Swine | 12 | 2023 | 730 | 0.440 |
Why?
|
Leukocytes | 4 | 2017 | 290 | 0.440 |
Why?
|
Wounds, Penetrating | 4 | 2018 | 77 | 0.440 |
Why?
|
Antibodies, Monoclonal | 4 | 2013 | 1284 | 0.430 |
Why?
|
Intercellular Signaling Peptides and Proteins | 4 | 2009 | 369 | 0.430 |
Why?
|
Cardiac Surgical Procedures | 2 | 2017 | 461 | 0.420 |
Why?
|
Blast Injuries | 2 | 2022 | 42 | 0.420 |
Why?
|
Translocation, Genetic | 2 | 2005 | 92 | 0.410 |
Why?
|
Acute Chest Syndrome | 1 | 2011 | 3 | 0.410 |
Why?
|
Phospholipases A2, Secretory | 1 | 2011 | 27 | 0.410 |
Why?
|
Splenomegaly | 1 | 2011 | 17 | 0.410 |
Why?
|
Hemodilution | 1 | 2011 | 10 | 0.410 |
Why?
|
Lipopolysaccharides | 9 | 2016 | 870 | 0.400 |
Why?
|
Hydroxyeicosatetraenoic Acids | 1 | 2011 | 41 | 0.400 |
Why?
|
Hemoglobin SC Disease | 1 | 2011 | 15 | 0.400 |
Why?
|
NADH, NADPH Oxidoreductases | 4 | 1996 | 18 | 0.400 |
Why?
|
Pneumonia | 2 | 2017 | 592 | 0.400 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2011 | 30 | 0.400 |
Why?
|
Heterotrimeric GTP-Binding Proteins | 1 | 2010 | 16 | 0.390 |
Why?
|
Risk Factors | 17 | 2022 | 9000 | 0.390 |
Why?
|
Shock, Traumatic | 2 | 2015 | 18 | 0.390 |
Why?
|
CD40 Ligand | 2 | 2011 | 46 | 0.390 |
Why?
|
Arrestins | 2 | 2010 | 15 | 0.380 |
Why?
|
Phenotype | 6 | 2019 | 3003 | 0.380 |
Why?
|
Estradiol | 3 | 2022 | 476 | 0.380 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 234 | 0.370 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2009 | 177 | 0.370 |
Why?
|
Abdominal Pain | 1 | 2011 | 133 | 0.370 |
Why?
|
Endosomes | 2 | 2008 | 128 | 0.370 |
Why?
|
Receptors, Cell Surface | 4 | 2003 | 367 | 0.360 |
Why?
|
Tyrosine | 4 | 2003 | 233 | 0.360 |
Why?
|
Isoantigens | 2 | 2006 | 19 | 0.360 |
Why?
|
Adenocarcinoma | 5 | 2012 | 812 | 0.360 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2013 | 402 | 0.350 |
Why?
|
Amantadine | 1 | 2009 | 7 | 0.350 |
Why?
|
Fibrin | 2 | 2022 | 60 | 0.350 |
Why?
|
Cardiopulmonary Bypass | 4 | 2008 | 203 | 0.340 |
Why?
|
Hemostatic Techniques | 3 | 2018 | 40 | 0.330 |
Why?
|
alpha-Globins | 2 | 2022 | 12 | 0.330 |
Why?
|
rab5 GTP-Binding Proteins | 1 | 2008 | 7 | 0.330 |
Why?
|
Cell Adhesion | 6 | 2013 | 443 | 0.330 |
Why?
|
Endovascular Procedures | 2 | 2023 | 276 | 0.330 |
Why?
|
Angiogenic Proteins | 1 | 2008 | 21 | 0.330 |
Why?
|
Adolescent | 24 | 2019 | 18480 | 0.330 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2023 | 613 | 0.320 |
Why?
|
Biomarkers | 12 | 2022 | 3588 | 0.320 |
Why?
|
Isotonic Solutions | 6 | 2016 | 43 | 0.320 |
Why?
|
Actins | 2 | 2009 | 404 | 0.310 |
Why?
|
Egtazic Acid | 4 | 2002 | 44 | 0.310 |
Why?
|
Carcinogens | 1 | 2008 | 108 | 0.310 |
Why?
|
Protein Transport | 4 | 2016 | 412 | 0.310 |
Why?
|
Splanchnic Circulation | 2 | 2004 | 12 | 0.300 |
Why?
|
Recombinant Proteins | 2 | 2016 | 1308 | 0.300 |
Why?
|
HLA Antigens | 5 | 2018 | 230 | 0.300 |
Why?
|
Brain Injuries | 2 | 2022 | 484 | 0.300 |
Why?
|
Trauma Severity Indices | 4 | 2020 | 127 | 0.300 |
Why?
|
Prognosis | 9 | 2022 | 3443 | 0.290 |
Why?
|
Azepines | 6 | 2001 | 74 | 0.290 |
Why?
|
Case-Control Studies | 10 | 2019 | 3171 | 0.290 |
Why?
|
Protein C | 2 | 2023 | 44 | 0.290 |
Why?
|
Organ Preservation Solutions | 2 | 2018 | 44 | 0.280 |
Why?
|
Arachidonate 5-Lipoxygenase | 2 | 2018 | 45 | 0.280 |
Why?
|
Models, Biological | 5 | 2009 | 1715 | 0.280 |
Why?
|
Liver Transplantation | 3 | 2017 | 847 | 0.280 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 341 | 0.280 |
Why?
|
Thromboplastin | 2 | 2023 | 68 | 0.280 |
Why?
|
Receptors, Peptide | 3 | 2003 | 24 | 0.270 |
Why?
|
Reperfusion Injury | 3 | 2018 | 276 | 0.270 |
Why?
|
Aged | 19 | 2019 | 19657 | 0.270 |
Why?
|
Factor VII | 2 | 2013 | 24 | 0.270 |
Why?
|
CD40 Antigens | 1 | 2006 | 80 | 0.270 |
Why?
|
Triazoles | 6 | 2001 | 134 | 0.270 |
Why?
|
Flow Cytometry | 6 | 2015 | 1085 | 0.260 |
Why?
|
Colorado | 11 | 2019 | 4196 | 0.260 |
Why?
|
Lymph Nodes | 3 | 2014 | 455 | 0.260 |
Why?
|
Reactive Oxygen Species | 3 | 2012 | 576 | 0.260 |
Why?
|
Up-Regulation | 6 | 2009 | 872 | 0.260 |
Why?
|
Enzyme Inhibitors | 7 | 2009 | 827 | 0.260 |
Why?
|
Peroxidase | 2 | 2003 | 170 | 0.260 |
Why?
|
Hemostatics | 2 | 2023 | 50 | 0.250 |
Why?
|
Receptors, Immunologic | 3 | 2003 | 209 | 0.250 |
Why?
|
Protein Subunits | 1 | 2005 | 211 | 0.250 |
Why?
|
Analysis of Variance | 6 | 2013 | 1293 | 0.250 |
Why?
|
Pulmonary Circulation | 1 | 2006 | 424 | 0.250 |
Why?
|
Arginine | 2 | 2022 | 249 | 0.240 |
Why?
|
Prostatectomy | 1 | 2004 | 100 | 0.240 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 1384 | 0.240 |
Why?
|
Postoperative Complications | 3 | 2004 | 2235 | 0.240 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 2004 | 15 | 0.240 |
Why?
|
Fluorescence Resonance Energy Transfer | 3 | 2010 | 183 | 0.240 |
Why?
|
Lactic Acid | 4 | 2018 | 282 | 0.240 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 1868 | 0.230 |
Why?
|
Models, Animal | 3 | 2017 | 363 | 0.230 |
Why?
|
Blood Physiological Phenomena | 1 | 2003 | 15 | 0.230 |
Why?
|
Hypocalcemia | 1 | 2023 | 31 | 0.230 |
Why?
|
Rodentia | 1 | 2023 | 47 | 0.230 |
Why?
|
Hypoxia | 2 | 2022 | 963 | 0.230 |
Why?
|
Compartment Syndromes | 1 | 2003 | 38 | 0.230 |
Why?
|
Imidazoles | 5 | 2003 | 232 | 0.230 |
Why?
|
Transcription Factors | 2 | 2003 | 1570 | 0.230 |
Why?
|
Hypotension | 1 | 2004 | 120 | 0.230 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2003 | 61 | 0.230 |
Why?
|
Acidosis | 2 | 2016 | 86 | 0.220 |
Why?
|
Serpins | 1 | 2022 | 26 | 0.220 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 93 | 0.220 |
Why?
|
von Willebrand Factor | 1 | 2022 | 58 | 0.220 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2022 | 80 | 0.220 |
Why?
|
Complement C4 | 1 | 2022 | 26 | 0.220 |
Why?
|
Hemophilia A | 2 | 2013 | 71 | 0.210 |
Why?
|
Capillary Permeability | 1 | 2022 | 140 | 0.210 |
Why?
|
Alcoholic Intoxication | 2 | 2020 | 63 | 0.210 |
Why?
|
Caspases | 1 | 2003 | 269 | 0.210 |
Why?
|
Hospital Mortality | 3 | 2017 | 814 | 0.210 |
Why?
|
Chromatography, High Pressure Liquid | 5 | 2018 | 490 | 0.210 |
Why?
|
Treatment Outcome | 10 | 2017 | 9342 | 0.200 |
Why?
|
Endothelium | 2 | 2016 | 120 | 0.200 |
Why?
|
Retrospective Studies | 13 | 2023 | 12978 | 0.200 |
Why?
|
Random Allocation | 4 | 2015 | 344 | 0.200 |
Why?
|
Asparaginase | 2 | 1998 | 30 | 0.200 |
Why?
|
Acute Disease | 5 | 2011 | 940 | 0.200 |
Why?
|
Mice | 12 | 2022 | 15520 | 0.200 |
Why?
|
Plasmapheresis | 1 | 2001 | 23 | 0.200 |
Why?
|
Pyridoxal Phosphate | 1 | 2001 | 21 | 0.200 |
Why?
|
Platelet Activation | 3 | 2022 | 70 | 0.200 |
Why?
|
Sex Factors | 6 | 2023 | 1781 | 0.200 |
Why?
|
Complement Activation | 2 | 2022 | 350 | 0.190 |
Why?
|
Tissue Extracts | 1 | 2000 | 20 | 0.190 |
Why?
|
Blood Volume | 2 | 2015 | 58 | 0.190 |
Why?
|
Blotting, Western | 3 | 2017 | 1194 | 0.190 |
Why?
|
Metabolic Networks and Pathways | 1 | 2022 | 176 | 0.190 |
Why?
|
Femoral Fractures | 2 | 2017 | 67 | 0.190 |
Why?
|
Young Adult | 10 | 2020 | 10793 | 0.190 |
Why?
|
Interleukin-6 | 3 | 2003 | 688 | 0.190 |
Why?
|
Pancreatitis | 2 | 1998 | 108 | 0.190 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2023 | 225 | 0.180 |
Why?
|
Pregnancy | 4 | 2022 | 5691 | 0.180 |
Why?
|
NF-kappa B | 4 | 2017 | 670 | 0.180 |
Why?
|
Pulmonary Embolism | 1 | 2022 | 183 | 0.180 |
Why?
|
Blood Viscosity | 2 | 2019 | 19 | 0.180 |
Why?
|
Cyclic GMP | 2 | 1997 | 109 | 0.180 |
Why?
|
Chemokines | 1 | 2021 | 230 | 0.180 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 175 | 0.180 |
Why?
|
Multivariate Analysis | 4 | 2015 | 1474 | 0.180 |
Why?
|
Myosins | 1 | 2019 | 130 | 0.170 |
Why?
|
Intracranial Hypertension | 1 | 2019 | 41 | 0.170 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 1795 | 0.170 |
Why?
|
Phospholipids | 1 | 2001 | 208 | 0.170 |
Why?
|
Factor XIII | 2 | 2023 | 8 | 0.170 |
Why?
|
beta-Arrestin 1 | 2 | 2010 | 6 | 0.170 |
Why?
|
beta-Arrestins | 2 | 2010 | 12 | 0.170 |
Why?
|
Complement Pathway, Alternative | 1 | 2020 | 117 | 0.170 |
Why?
|
Hydrogen-Ion Concentration | 3 | 2018 | 536 | 0.170 |
Why?
|
Blood Buffy Coat | 1 | 2018 | 6 | 0.170 |
Why?
|
Monomeric Clathrin Assembly Proteins | 1 | 1998 | 5 | 0.170 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 13 | 0.170 |
Why?
|
Methods | 1 | 2018 | 67 | 0.170 |
Why?
|
Testosterone | 1 | 2022 | 351 | 0.170 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 1998 | 20 | 0.170 |
Why?
|
Phosphatidic Acids | 1 | 1998 | 9 | 0.170 |
Why?
|
5-Lipoxygenase-Activating Proteins | 1 | 2018 | 5 | 0.170 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1998 | 66 | 0.160 |
Why?
|
Pyridines | 4 | 2003 | 440 | 0.160 |
Why?
|
Blood Pressure | 4 | 2014 | 1664 | 0.160 |
Why?
|
Fluid Therapy | 2 | 2016 | 131 | 0.160 |
Why?
|
Hemagglutinins | 1 | 2018 | 11 | 0.160 |
Why?
|
Microscopy, Fluorescence | 2 | 2010 | 412 | 0.160 |
Why?
|
Culture Media, Conditioned | 2 | 2017 | 112 | 0.160 |
Why?
|
Ambulances | 1 | 2018 | 49 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2012 | 527 | 0.160 |
Why?
|
Alprostadil | 1 | 1998 | 32 | 0.160 |
Why?
|
Blood Bactericidal Activity | 1 | 1998 | 37 | 0.160 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2014 | 1945 | 0.160 |
Why?
|
Endopeptidases | 1 | 1998 | 73 | 0.160 |
Why?
|
Cycloheximide | 1 | 2018 | 57 | 0.160 |
Why?
|
Solutions | 1 | 2018 | 156 | 0.160 |
Why?
|
Angiostatins | 1 | 2017 | 4 | 0.160 |
Why?
|
Octreotide | 1 | 1998 | 27 | 0.160 |
Why?
|
Chelating Agents | 4 | 2002 | 74 | 0.160 |
Why?
|
Glycolysis | 2 | 2018 | 224 | 0.160 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2018 | 47 | 0.160 |
Why?
|
Histocompatibility Testing | 1 | 2018 | 123 | 0.160 |
Why?
|
Molsidomine | 1 | 1997 | 6 | 0.160 |
Why?
|
Venous Thrombosis | 1 | 2019 | 147 | 0.160 |
Why?
|
Dynamin II | 2 | 2008 | 8 | 0.150 |
Why?
|
Receptors, Formyl Peptide | 3 | 2003 | 11 | 0.150 |
Why?
|
Fracture Fixation, Intramedullary | 1 | 1998 | 54 | 0.150 |
Why?
|
Signal Transduction | 8 | 2017 | 4709 | 0.150 |
Why?
|
Incidence | 4 | 2019 | 2424 | 0.150 |
Why?
|
Prostatic Neoplasms | 1 | 2004 | 940 | 0.150 |
Why?
|
Gene Expression Regulation | 2 | 2004 | 2445 | 0.150 |
Why?
|
Freeze Drying | 1 | 2017 | 75 | 0.150 |
Why?
|
Isoproterenol | 1 | 1997 | 125 | 0.150 |
Why?
|
Alternative Splicing | 1 | 1998 | 193 | 0.150 |
Why?
|
Cohort Studies | 7 | 2023 | 5116 | 0.150 |
Why?
|
Myocardium | 2 | 2019 | 970 | 0.150 |
Why?
|
Cell Movement | 3 | 2017 | 896 | 0.150 |
Why?
|
Consensus | 1 | 2019 | 534 | 0.140 |
Why?
|
Oncogene Proteins, Fusion | 1 | 1998 | 181 | 0.140 |
Why?
|
Adrenergic beta-Agonists | 1 | 1997 | 132 | 0.140 |
Why?
|
Cell Death | 1 | 1998 | 339 | 0.140 |
Why?
|
Bone Marrow | 1 | 1998 | 255 | 0.140 |
Why?
|
Group II Phospholipases A2 | 3 | 2002 | 23 | 0.140 |
Why?
|
Receptors, Adrenergic, beta | 1 | 1997 | 144 | 0.140 |
Why?
|
Precision Medicine | 1 | 2020 | 363 | 0.140 |
Why?
|
Nitric Oxide | 2 | 2022 | 892 | 0.140 |
Why?
|
Critical Care | 4 | 2015 | 492 | 0.140 |
Why?
|
Calcium-Binding Proteins | 1 | 1997 | 217 | 0.140 |
Why?
|
Perioperative Care | 1 | 2017 | 132 | 0.140 |
Why?
|
Brain Death | 1 | 2016 | 29 | 0.140 |
Why?
|
Platelet Count | 2 | 2013 | 83 | 0.140 |
Why?
|
Cell Communication | 2 | 2013 | 281 | 0.140 |
Why?
|
Hemodynamics | 2 | 2015 | 1004 | 0.140 |
Why?
|
Risk Assessment | 8 | 2021 | 3057 | 0.140 |
Why?
|
Phosphates | 2 | 2014 | 167 | 0.140 |
Why?
|
Metabolic Flux Analysis | 1 | 2015 | 7 | 0.140 |
Why?
|
Chemotaxis, Leukocyte | 2 | 2009 | 133 | 0.140 |
Why?
|
Protein Biosynthesis | 1 | 2018 | 397 | 0.130 |
Why?
|
Taurocholic Acid | 1 | 2015 | 34 | 0.130 |
Why?
|
Goals | 1 | 2017 | 167 | 0.130 |
Why?
|
Ligands | 2 | 2008 | 567 | 0.130 |
Why?
|
Purines | 1 | 2016 | 161 | 0.130 |
Why?
|
Patient Selection | 2 | 2018 | 676 | 0.130 |
Why?
|
Disease Management | 1 | 2019 | 571 | 0.130 |
Why?
|
Isotope Labeling | 1 | 2015 | 76 | 0.130 |
Why?
|
Citrates | 1 | 2014 | 48 | 0.130 |
Why?
|
Phospholipases A2 | 3 | 2000 | 77 | 0.130 |
Why?
|
Oxidative Stress | 4 | 2014 | 1178 | 0.130 |
Why?
|
Elasticity | 1 | 2015 | 193 | 0.130 |
Why?
|
Intensive Care Units | 2 | 2010 | 635 | 0.130 |
Why?
|
International Normalized Ratio | 3 | 2019 | 45 | 0.130 |
Why?
|
Abdomen, Acute | 1 | 1994 | 20 | 0.130 |
Why?
|
Epithelial Cells | 2 | 2017 | 963 | 0.120 |
Why?
|
Nerve Tissue Proteins | 1 | 1998 | 551 | 0.120 |
Why?
|
Critical Illness | 2 | 2017 | 662 | 0.120 |
Why?
|
2,3-Diphosphoglycerate | 1 | 2014 | 29 | 0.120 |
Why?
|
Immunoglobulin M | 1 | 1995 | 253 | 0.120 |
Why?
|
Heinz Bodies | 1 | 2014 | 1 | 0.120 |
Why?
|
Carbon | 1 | 2015 | 170 | 0.120 |
Why?
|
Child, Preschool | 8 | 2016 | 9491 | 0.120 |
Why?
|
Macrophages | 2 | 2012 | 1324 | 0.120 |
Why?
|
Erythrocytes, Abnormal | 1 | 2014 | 16 | 0.120 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1993 | 2 | 0.120 |
Why?
|
Pertussis Toxin | 2 | 2003 | 29 | 0.120 |
Why?
|
Pilot Projects | 3 | 2018 | 1419 | 0.120 |
Why?
|
Respiratory Insufficiency | 1 | 2017 | 290 | 0.120 |
Why?
|
Deferoxamine | 1 | 1993 | 17 | 0.120 |
Why?
|
Hemosiderosis | 1 | 1993 | 3 | 0.120 |
Why?
|
Codon | 1 | 2014 | 89 | 0.120 |
Why?
|
ROC Curve | 3 | 2021 | 473 | 0.120 |
Why?
|
Energy Metabolism | 2 | 2017 | 767 | 0.120 |
Why?
|
Emergency Medical Services | 2 | 2018 | 589 | 0.120 |
Why?
|
Ethanol | 1 | 1998 | 575 | 0.110 |
Why?
|
Protein Stability | 1 | 2014 | 164 | 0.110 |
Why?
|
Child | 11 | 2019 | 19129 | 0.110 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1993 | 9 | 0.110 |
Why?
|
Coagulants | 1 | 2013 | 12 | 0.110 |
Why?
|
Heterozygote | 1 | 2014 | 262 | 0.110 |
Why?
|
Adenine | 1 | 2014 | 223 | 0.110 |
Why?
|
Amino Acid Substitution | 1 | 2014 | 276 | 0.110 |
Why?
|
Early Diagnosis | 1 | 2014 | 230 | 0.110 |
Why?
|
Linear Models | 1 | 2015 | 827 | 0.110 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2012 | 25 | 0.110 |
Why?
|
Isoflurane | 1 | 2012 | 8 | 0.110 |
Why?
|
Siblings | 1 | 2014 | 235 | 0.110 |
Why?
|
Anesthetics, Inhalation | 1 | 2012 | 14 | 0.110 |
Why?
|
Amino Acids | 1 | 2016 | 465 | 0.110 |
Why?
|
Friend murine leukemia virus | 1 | 1993 | 30 | 0.110 |
Why?
|
Exsanguination | 1 | 2012 | 16 | 0.110 |
Why?
|
CD11 Antigens | 3 | 2003 | 32 | 0.110 |
Why?
|
Soft Tissue Neoplasms | 1 | 1993 | 93 | 0.110 |
Why?
|
Paecilomyces | 1 | 1992 | 2 | 0.110 |
Why?
|
Blood Platelet Disorders | 1 | 2012 | 10 | 0.110 |
Why?
|
Abdominal Muscles | 1 | 1992 | 7 | 0.110 |
Why?
|
Logistic Models | 4 | 2020 | 1901 | 0.110 |
Why?
|
Interleukin-1beta | 1 | 2014 | 379 | 0.110 |
Why?
|
Platelet-Derived Growth Factor | 2 | 2012 | 83 | 0.110 |
Why?
|
Cross-Linking Reagents | 2 | 2006 | 186 | 0.100 |
Why?
|
Neoplasm Metastasis | 2 | 2013 | 544 | 0.100 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1993 | 224 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2017 | 516 | 0.100 |
Why?
|
Adenosine Triphosphate | 1 | 2014 | 439 | 0.100 |
Why?
|
Granulomatous Disease, Chronic | 1 | 1992 | 61 | 0.100 |
Why?
|
Encephalitis | 1 | 1993 | 129 | 0.100 |
Why?
|
DNA-Binding Proteins | 1 | 1999 | 1346 | 0.100 |
Why?
|
beta 2-Microglobulin | 1 | 2011 | 47 | 0.100 |
Why?
|
Antigens, CD | 2 | 2008 | 460 | 0.100 |
Why?
|
Mycoses | 1 | 1992 | 69 | 0.100 |
Why?
|
Immunoglobulin G | 1 | 1995 | 788 | 0.100 |
Why?
|
Extravascular Lung Water | 1 | 2011 | 9 | 0.100 |
Why?
|
Abscess | 1 | 1992 | 75 | 0.100 |
Why?
|
Immunocompromised Host | 2 | 2008 | 200 | 0.100 |
Why?
|
I-kappa B Proteins | 2 | 2003 | 80 | 0.100 |
Why?
|
Vitamin K Deficiency | 1 | 1991 | 10 | 0.100 |
Why?
|
Splenectomy | 1 | 2011 | 57 | 0.100 |
Why?
|
G-Protein-Coupled Receptor Kinases | 1 | 2010 | 3 | 0.100 |
Why?
|
GTP-Binding Protein gamma Subunits | 1 | 2010 | 8 | 0.100 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 1991 | 16 | 0.100 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2010 | 13 | 0.100 |
Why?
|
GTP-Binding Protein beta Subunits | 1 | 2010 | 14 | 0.100 |
Why?
|
Hypothermia | 1 | 2011 | 32 | 0.100 |
Why?
|
Drug Design | 1 | 2012 | 160 | 0.100 |
Why?
|
Calcium Signaling | 2 | 2003 | 219 | 0.100 |
Why?
|
Ion Transport | 1 | 2010 | 60 | 0.100 |
Why?
|
Histones | 3 | 2022 | 552 | 0.100 |
Why?
|
Protein Binding | 1 | 2016 | 1975 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2016 | 540 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 811 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2013 | 240 | 0.090 |
Why?
|
Aorta | 2 | 2023 | 367 | 0.090 |
Why?
|
Oxidation-Reduction | 3 | 2018 | 940 | 0.090 |
Why?
|
alpha 1-Antitrypsin | 1 | 2011 | 115 | 0.090 |
Why?
|
Injections, Intravenous | 1 | 2010 | 210 | 0.090 |
Why?
|
Peritoneal Neoplasms | 1 | 2010 | 53 | 0.090 |
Why?
|
Infant, Newborn | 3 | 2005 | 5255 | 0.090 |
Why?
|
Muscle, Skeletal | 1 | 2019 | 1515 | 0.090 |
Why?
|
Chemotaxis | 2 | 2017 | 137 | 0.090 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2009 | 55 | 0.090 |
Why?
|
Anemia, Sickle Cell | 1 | 1993 | 230 | 0.090 |
Why?
|
Capillary Leak Syndrome | 1 | 2009 | 13 | 0.090 |
Why?
|
Mice, Knockout | 1 | 2016 | 2680 | 0.090 |
Why?
|
Membrane Microdomains | 1 | 2009 | 35 | 0.090 |
Why?
|
Glasgow Coma Scale | 2 | 2023 | 150 | 0.090 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 109 | 0.090 |
Why?
|
Glucose | 1 | 2014 | 953 | 0.090 |
Why?
|
Rimantadine | 1 | 2009 | 3 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2010 | 307 | 0.090 |
Why?
|
Partial Thromboplastin Time | 2 | 2019 | 52 | 0.090 |
Why?
|
Parity | 1 | 2009 | 101 | 0.090 |
Why?
|
Herpes Zoster | 1 | 1993 | 336 | 0.090 |
Why?
|
Tetrahydronaphthalenes | 2 | 2020 | 32 | 0.090 |
Why?
|
HMGB1 Protein | 1 | 2009 | 49 | 0.090 |
Why?
|
Immunoblotting | 1 | 2009 | 307 | 0.090 |
Why?
|
Heme Oxygenase-1 | 1 | 2009 | 53 | 0.090 |
Why?
|
Antigens, CD1 | 1 | 2009 | 60 | 0.090 |
Why?
|
Cell Line, Tumor | 3 | 2012 | 2851 | 0.090 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 1999 | 155 | 0.080 |
Why?
|
RNA Interference | 1 | 2011 | 460 | 0.080 |
Why?
|
Organ Specificity | 1 | 2009 | 278 | 0.080 |
Why?
|
Granulocytes | 2 | 2000 | 79 | 0.080 |
Why?
|
Kaolin | 2 | 2018 | 5 | 0.080 |
Why?
|
Cross Infection | 1 | 2011 | 205 | 0.080 |
Why?
|
Transcription, Genetic | 1 | 2014 | 1323 | 0.080 |
Why?
|
Fluorescent Dyes | 2 | 2002 | 316 | 0.080 |
Why?
|
Blood Banks | 2 | 2015 | 43 | 0.080 |
Why?
|
Adaptive Immunity | 1 | 2009 | 161 | 0.080 |
Why?
|
Chondroblastoma | 1 | 1987 | 4 | 0.080 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2008 | 91 | 0.080 |
Why?
|
Molecular Weight | 2 | 2003 | 343 | 0.080 |
Why?
|
Bevacizumab | 1 | 2008 | 124 | 0.080 |
Why?
|
Antigens | 1 | 2009 | 320 | 0.080 |
Why?
|
Microtubule-Associated Proteins | 1 | 1989 | 188 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2012 | 527 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2009 | 227 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2017 | 6561 | 0.080 |
Why?
|
Vesicular Transport Proteins | 1 | 2008 | 84 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1987 | 66 | 0.080 |
Why?
|
Calcium Channel Blockers | 2 | 1998 | 117 | 0.080 |
Why?
|
Risk | 2 | 2001 | 853 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 1998 | 1974 | 0.070 |
Why?
|
Osteosarcoma | 1 | 1987 | 71 | 0.070 |
Why?
|
Indoles | 2 | 2001 | 316 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 709 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 693 | 0.070 |
Why?
|
MAP Kinase Kinase Kinase 5 | 1 | 2006 | 4 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2012 | 2674 | 0.070 |
Why?
|
Probability | 2 | 2004 | 305 | 0.070 |
Why?
|
Kidney | 1 | 2014 | 1353 | 0.070 |
Why?
|
Antigen-Antibody Reactions | 1 | 2006 | 51 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 1 | 2008 | 219 | 0.070 |
Why?
|
Immune Tolerance | 1 | 2008 | 334 | 0.070 |
Why?
|
Leukotrienes | 2 | 2018 | 35 | 0.070 |
Why?
|
Interleukin-10 | 2 | 2012 | 306 | 0.070 |
Why?
|
Subcellular Fractions | 1 | 2006 | 84 | 0.070 |
Why?
|
Obesity | 1 | 2019 | 2746 | 0.070 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 287 | 0.070 |
Why?
|
Coculture Techniques | 1 | 2006 | 208 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2017 | 4596 | 0.070 |
Why?
|
Erythroblastosis, Fetal | 1 | 2005 | 4 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2008 | 1965 | 0.070 |
Why?
|
Chemokine CCL5 | 2 | 2017 | 48 | 0.070 |
Why?
|
Transplantation Conditioning | 2 | 2016 | 156 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2008 | 359 | 0.070 |
Why?
|
Gas Chromatography-Mass Spectrometry | 2 | 2018 | 135 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2008 | 462 | 0.070 |
Why?
|
Sodium Dodecyl Sulfate | 1 | 2005 | 20 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 1987 | 199 | 0.070 |
Why?
|
Microfilament Proteins | 1 | 2006 | 134 | 0.070 |
Why?
|
Cell Differentiation | 1 | 1993 | 1753 | 0.070 |
Why?
|
Potassium Compounds | 1 | 2005 | 9 | 0.070 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 106 | 0.070 |
Why?
|
Pulmonary Artery | 2 | 2003 | 1063 | 0.060 |
Why?
|
Intraoperative Care | 1 | 2004 | 39 | 0.060 |
Why?
|
Cytochromes c | 1 | 2004 | 64 | 0.060 |
Why?
|
Sampling Studies | 1 | 2004 | 92 | 0.060 |
Why?
|
Factor VIIa | 1 | 2004 | 36 | 0.060 |
Why?
|
Cluster Analysis | 2 | 2016 | 481 | 0.060 |
Why?
|
Infant | 3 | 2016 | 8293 | 0.060 |
Why?
|
Immunity, Innate | 1 | 2009 | 745 | 0.060 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2008 | 667 | 0.060 |
Why?
|
Databases, Factual | 2 | 2017 | 1231 | 0.060 |
Why?
|
Blood Group Incompatibility | 2 | 2018 | 15 | 0.060 |
Why?
|
Interleukin-11 | 1 | 2003 | 10 | 0.060 |
Why?
|
Lactoferrin | 1 | 2003 | 29 | 0.060 |
Why?
|
Factor V | 1 | 2023 | 23 | 0.060 |
Why?
|
Cell Survival | 1 | 2006 | 1047 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 2436 | 0.060 |
Why?
|
Hematologic Neoplasms | 1 | 2004 | 133 | 0.060 |
Why?
|
Acute-Phase Proteins | 2 | 2014 | 67 | 0.060 |
Why?
|
Caspase Inhibitors | 1 | 2003 | 82 | 0.060 |
Why?
|
Substrate Specificity | 2 | 1997 | 371 | 0.060 |
Why?
|
Mutation | 1 | 2014 | 3457 | 0.060 |
Why?
|
Group IB Phospholipases A2 | 1 | 2002 | 2 | 0.060 |
Why?
|
Receptors, Phospholipase A2 | 1 | 2002 | 2 | 0.060 |
Why?
|
Reperfusion | 1 | 2023 | 43 | 0.060 |
Why?
|
E-Selectin | 1 | 2003 | 52 | 0.060 |
Why?
|
Survival Rate | 2 | 2018 | 1720 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2010 | 2275 | 0.060 |
Why?
|
Arginase | 1 | 2022 | 29 | 0.060 |
Why?
|
Perfusion | 1 | 2003 | 153 | 0.060 |
Why?
|
P-Selectin | 1 | 2022 | 26 | 0.050 |
Why?
|
Education, Medical, Continuing | 1 | 2004 | 125 | 0.050 |
Why?
|
Serine | 1 | 2003 | 138 | 0.050 |
Why?
|
Citrulline | 1 | 2022 | 41 | 0.050 |
Why?
|
Apolipoprotein A-I | 1 | 2022 | 26 | 0.050 |
Why?
|
Binding, Competitive | 1 | 2002 | 205 | 0.050 |
Why?
|
Cell Size | 1 | 2002 | 86 | 0.050 |
Why?
|
CD36 Antigens | 1 | 2022 | 42 | 0.050 |
Why?
|
Caspase 3 | 1 | 2003 | 243 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 310 | 0.050 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2022 | 95 | 0.050 |
Why?
|
United States | 4 | 2019 | 12555 | 0.050 |
Why?
|
Transcription Factor RelA | 2 | 2014 | 82 | 0.050 |
Why?
|
Cell Adhesion Molecules | 1 | 2003 | 180 | 0.050 |
Why?
|
Mitochondrial Proteins | 2 | 2015 | 226 | 0.050 |
Why?
|
Brachytherapy | 1 | 2002 | 103 | 0.050 |
Why?
|
Cell Line | 4 | 2014 | 2707 | 0.050 |
Why?
|
Cell Separation | 1 | 2002 | 296 | 0.050 |
Why?
|
Tissue Preservation | 1 | 2001 | 13 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2006 | 969 | 0.050 |
Why?
|
Oligopeptides | 1 | 2003 | 252 | 0.050 |
Why?
|
Wilms Tumor | 1 | 2002 | 69 | 0.050 |
Why?
|
Chromatography, Liquid | 2 | 2014 | 355 | 0.050 |
Why?
|
Maleimides | 1 | 2001 | 23 | 0.050 |
Why?
|
Cerebrovascular Circulation | 1 | 2023 | 204 | 0.050 |
Why?
|
Graft Rejection | 1 | 2004 | 555 | 0.050 |
Why?
|
Polymyxin B | 1 | 2000 | 22 | 0.050 |
Why?
|
Cell Nucleus | 2 | 2017 | 580 | 0.050 |
Why?
|
Tandem Mass Spectrometry | 2 | 2014 | 421 | 0.050 |
Why?
|
Elapid Venoms | 1 | 2020 | 16 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2012 | 874 | 0.050 |
Why?
|
Blood | 2 | 2005 | 100 | 0.050 |
Why?
|
Cyclic AMP | 2 | 1993 | 242 | 0.050 |
Why?
|
Fatty Acids | 1 | 2023 | 407 | 0.050 |
Why?
|
Drug Synergism | 1 | 2001 | 339 | 0.050 |
Why?
|
Research Design | 2 | 2017 | 969 | 0.050 |
Why?
|
Neutrophil Infiltration | 2 | 2012 | 97 | 0.050 |
Why?
|
Kinetics | 2 | 1997 | 1624 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2003 | 407 | 0.050 |
Why?
|
Neoplasms | 1 | 1994 | 2179 | 0.050 |
Why?
|
Receptors, Fibrinogen | 1 | 2019 | 2 | 0.050 |
Why?
|
Hematocrit | 1 | 2000 | 91 | 0.050 |
Why?
|
Aniline Compounds | 1 | 2020 | 71 | 0.050 |
Why?
|
Coagulation Protein Disorders | 1 | 2019 | 1 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 420 | 0.050 |
Why?
|
Societies, Medical | 1 | 2004 | 703 | 0.040 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 60 | 0.040 |
Why?
|
Specimen Handling | 1 | 2001 | 165 | 0.040 |
Why?
|
Complement Inactivating Agents | 1 | 2020 | 43 | 0.040 |
Why?
|
Ischemia | 1 | 2023 | 374 | 0.040 |
Why?
|
Blood Coagulation Factors | 1 | 2019 | 43 | 0.040 |
Why?
|
Protective Factors | 1 | 2019 | 92 | 0.040 |
Why?
|
Premenopause | 1 | 2019 | 108 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2000 | 180 | 0.040 |
Why?
|
Rhodamines | 1 | 1999 | 19 | 0.040 |
Why?
|
Water | 1 | 2022 | 425 | 0.040 |
Why?
|
Elapidae | 1 | 1998 | 5 | 0.040 |
Why?
|
Torso | 1 | 2019 | 30 | 0.040 |
Why?
|
Nitrates | 1 | 1999 | 78 | 0.040 |
Why?
|
Sheep | 2 | 2012 | 764 | 0.040 |
Why?
|
Nitrites | 1 | 1999 | 81 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1998 | 70 | 0.040 |
Why?
|
Delphi Technique | 1 | 2019 | 164 | 0.040 |
Why?
|
Sialoglycoproteins | 1 | 1999 | 162 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2012 | 1691 | 0.040 |
Why?
|
Endothelial Growth Factors | 1 | 1998 | 55 | 0.040 |
Why?
|
Mibefradil | 1 | 1998 | 6 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 1998 | 48 | 0.040 |
Why?
|
Lymphokines | 1 | 1998 | 122 | 0.040 |
Why?
|
Citric Acid | 1 | 2018 | 34 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1998 | 82 | 0.040 |
Why?
|
Gene Expression | 1 | 2003 | 1489 | 0.040 |
Why?
|
RNA | 1 | 2004 | 833 | 0.040 |
Why?
|
Peptides, Cyclic | 1 | 2020 | 260 | 0.040 |
Why?
|
Disease Progression | 2 | 2017 | 2490 | 0.040 |
Why?
|
CHO Cells | 1 | 1998 | 143 | 0.040 |
Why?
|
Extremities | 1 | 2019 | 113 | 0.040 |
Why?
|
Interferon Regulatory Factor-1 | 1 | 2017 | 13 | 0.040 |
Why?
|
Leukotriene E4 | 1 | 1998 | 29 | 0.040 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2017 | 16 | 0.040 |
Why?
|
Canada | 1 | 2019 | 340 | 0.040 |
Why?
|
Capillaries | 1 | 1998 | 103 | 0.040 |
Why?
|
DNA, Complementary | 1 | 1998 | 268 | 0.040 |
Why?
|
Cytochrome c Group | 1 | 1997 | 37 | 0.040 |
Why?
|
Antibody Affinity | 1 | 2018 | 55 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2021 | 749 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 1998 | 154 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2002 | 334 | 0.040 |
Why?
|
Cricetinae | 1 | 1998 | 262 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2019 | 211 | 0.040 |
Why?
|
Dibutyryl Cyclic GMP | 1 | 1997 | 2 | 0.040 |
Why?
|
Laparoscopy | 1 | 2002 | 417 | 0.040 |
Why?
|
Crush Injuries | 1 | 2017 | 10 | 0.040 |
Why?
|
Area Under Curve | 1 | 2018 | 296 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2018 | 184 | 0.040 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 256 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 1998 | 413 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2018 | 143 | 0.040 |
Why?
|
STAT1 Transcription Factor | 1 | 2017 | 69 | 0.040 |
Why?
|
Postmenopause | 1 | 2019 | 305 | 0.040 |
Why?
|
Exons | 1 | 1998 | 307 | 0.040 |
Why?
|
Swine, Miniature | 1 | 2017 | 71 | 0.040 |
Why?
|
Colforsin | 1 | 1997 | 55 | 0.040 |
Why?
|
Lactates | 1 | 2017 | 87 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 1998 | 102 | 0.040 |
Why?
|
Species Specificity | 1 | 1999 | 565 | 0.040 |
Why?
|
Anaerobiosis | 1 | 2017 | 50 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2017 | 79 | 0.040 |
Why?
|
Survival Analysis | 2 | 2015 | 1267 | 0.040 |
Why?
|
Primates | 1 | 2018 | 114 | 0.040 |
Why?
|
Autoantibodies | 1 | 2004 | 1335 | 0.040 |
Why?
|
Benzimidazoles | 1 | 1998 | 140 | 0.040 |
Why?
|
Calcium Channels | 1 | 1997 | 150 | 0.040 |
Why?
|
Quality Control | 1 | 2017 | 159 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2002 | 900 | 0.040 |
Why?
|
Glutamine | 1 | 2016 | 88 | 0.040 |
Why?
|
Discriminant Analysis | 1 | 2016 | 41 | 0.040 |
Why?
|
Sex Distribution | 2 | 2010 | 351 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 73 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 1998 | 2871 | 0.040 |
Why?
|
Needs Assessment | 1 | 2018 | 327 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2002 | 1055 | 0.030 |
Why?
|
Military Personnel | 2 | 2014 | 529 | 0.030 |
Why?
|
Transfection | 1 | 1998 | 888 | 0.030 |
Why?
|
Oxygen | 1 | 2000 | 854 | 0.030 |
Why?
|
Epitopes | 1 | 2018 | 443 | 0.030 |
Why?
|
Systems Theory | 1 | 2015 | 5 | 0.030 |
Why?
|
Spleen | 1 | 2017 | 510 | 0.030 |
Why?
|
Self Report | 1 | 2019 | 699 | 0.030 |
Why?
|
Alarmins | 1 | 2015 | 25 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2002 | 1166 | 0.030 |
Why?
|
Bacterial Translocation | 1 | 2015 | 36 | 0.030 |
Why?
|
Length of Stay | 2 | 2011 | 1032 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2017 | 225 | 0.030 |
Why?
|
Gelsolin | 1 | 2014 | 9 | 0.030 |
Why?
|
Postoperative Period | 1 | 2016 | 309 | 0.030 |
Why?
|
Serine Proteases | 1 | 2014 | 15 | 0.030 |
Why?
|
Kallikreins | 1 | 2014 | 33 | 0.030 |
Why?
|
Pandemics | 1 | 2023 | 1355 | 0.030 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 1994 | 21 | 0.030 |
Why?
|
Thoracotomy | 1 | 2015 | 84 | 0.030 |
Why?
|
Warfare | 1 | 2015 | 77 | 0.030 |
Why?
|
Down-Regulation | 1 | 1997 | 627 | 0.030 |
Why?
|
Hyperglycemia | 1 | 2018 | 312 | 0.030 |
Why?
|
Base Sequence | 1 | 1998 | 2159 | 0.030 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 1994 | 20 | 0.030 |
Why?
|
Intestines | 1 | 2017 | 332 | 0.030 |
Why?
|
Interleukin-1 | 1 | 1999 | 980 | 0.030 |
Why?
|
Phagocytosis | 1 | 2016 | 364 | 0.030 |
Why?
|
Cold Temperature | 1 | 2014 | 132 | 0.030 |
Why?
|
Reference Values | 1 | 1995 | 774 | 0.030 |
Why?
|
Acetylation | 1 | 1994 | 217 | 0.030 |
Why?
|
Peptide Hydrolases | 1 | 2014 | 108 | 0.030 |
Why?
|
Fetal Blood | 1 | 1995 | 272 | 0.030 |
Why?
|
Laparotomy | 1 | 1994 | 106 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2017 | 378 | 0.030 |
Why?
|
Extracellular Matrix Proteins | 1 | 2014 | 133 | 0.030 |
Why?
|
Iron Chelating Agents | 1 | 1993 | 17 | 0.030 |
Why?
|
Military Medicine | 1 | 2015 | 94 | 0.030 |
Why?
|
Emergencies | 1 | 1994 | 153 | 0.030 |
Why?
|
Radioimmunoassay | 1 | 1993 | 165 | 0.030 |
Why?
|
Aphidicolin | 1 | 1993 | 6 | 0.030 |
Why?
|
Brain | 2 | 2016 | 2490 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2013 | 35 | 0.030 |
Why?
|
Factor VIII | 1 | 2013 | 56 | 0.030 |
Why?
|
Dimethyl Sulfoxide | 1 | 1993 | 45 | 0.030 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2012 | 6 | 0.030 |
Why?
|
Appendicitis | 1 | 1994 | 125 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2013 | 63 | 0.030 |
Why?
|
Receptors, Purinergic P2 | 1 | 2012 | 20 | 0.030 |
Why?
|
Registries | 2 | 2015 | 1810 | 0.030 |
Why?
|
Physical Examination | 1 | 1994 | 243 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2013 | 305 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2013 | 173 | 0.030 |
Why?
|
Nebulizers and Vaporizers | 1 | 2012 | 82 | 0.030 |
Why?
|
Amphotericin B | 1 | 1992 | 31 | 0.030 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2012 | 62 | 0.030 |
Why?
|
Ticlopidine | 1 | 2012 | 61 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2014 | 586 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2012 | 190 | 0.030 |
Why?
|
Stromal Cells | 1 | 2012 | 102 | 0.030 |
Why?
|
Body Mass Index | 1 | 2019 | 2092 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2012 | 126 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2012 | 4908 | 0.030 |
Why?
|
Photochemistry | 1 | 2012 | 136 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2012 | 410 | 0.030 |
Why?
|
Iron | 1 | 1993 | 248 | 0.030 |
Why?
|
Radiography | 1 | 1994 | 861 | 0.030 |
Why?
|
Whole Blood Coagulation Time | 1 | 1991 | 3 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 589 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2012 | 158 | 0.020 |
Why?
|
Macrophage Activation | 1 | 2012 | 168 | 0.020 |
Why?
|
Feces | 1 | 1993 | 396 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2011 | 136 | 0.020 |
Why?
|
Emergency Medicine | 1 | 2014 | 238 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2012 | 656 | 0.020 |
Why?
|
Perioperative Period | 1 | 2010 | 51 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 332 | 0.020 |
Why?
|
Zinc | 1 | 1993 | 262 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 1998 | 1022 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2017 | 1774 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2010 | 62 | 0.020 |
Why?
|
Diarrhea | 1 | 1991 | 181 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 525 | 0.020 |
Why?
|
Herpesvirus 3, Human | 1 | 1993 | 389 | 0.020 |
Why?
|
Cell Transplantation | 1 | 2009 | 39 | 0.020 |
Why?
|
Chymotrypsin | 1 | 1989 | 21 | 0.020 |
Why?
|
Protoporphyrins | 1 | 2009 | 17 | 0.020 |
Why?
|
Enzyme Induction | 1 | 2009 | 94 | 0.020 |
Why?
|
Leukosialin | 1 | 2008 | 15 | 0.020 |
Why?
|
Lymphocytes | 1 | 2011 | 347 | 0.020 |
Why?
|
Recurrence | 1 | 1992 | 975 | 0.020 |
Why?
|
Paracrine Communication | 1 | 2009 | 57 | 0.020 |
Why?
|
Lymphocyte Depletion | 1 | 2009 | 119 | 0.020 |
Why?
|
Double-Blind Method | 1 | 1993 | 1687 | 0.020 |
Why?
|
CD11b Antigen | 1 | 2008 | 59 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2009 | 113 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2011 | 446 | 0.020 |
Why?
|
Tubulin | 1 | 1989 | 122 | 0.020 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2008 | 24 | 0.020 |
Why?
|
Shock | 1 | 2009 | 92 | 0.020 |
Why?
|
Odds Ratio | 1 | 2011 | 996 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2010 | 454 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 1244 | 0.020 |
Why?
|
Comorbidity | 1 | 2012 | 1527 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2011 | 726 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 462 | 0.020 |
Why?
|
Models, Statistical | 1 | 2010 | 636 | 0.020 |
Why?
|
Cattle | 1 | 1989 | 978 | 0.020 |
Why?
|
Binding Sites | 1 | 1989 | 1224 | 0.020 |
Why?
|
Prevalence | 1 | 2012 | 2326 | 0.020 |
Why?
|
Extracorporeal Circulation | 1 | 2005 | 15 | 0.020 |
Why?
|
Body Weight | 1 | 2010 | 934 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 1067 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1989 | 702 | 0.020 |
Why?
|
Syndrome | 1 | 2005 | 344 | 0.020 |
Why?
|
Global Health | 1 | 2005 | 310 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2005 | 806 | 0.010 |
Why?
|
Kidney Pelvis | 1 | 2002 | 21 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 2995 | 0.010 |
Why?
|
Age Distribution | 1 | 2002 | 362 | 0.010 |
Why?
|
Umbilical Veins | 1 | 2001 | 59 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2001 | 287 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 1999 | 154 | 0.010 |
Why?
|
Megakaryocytes | 1 | 1998 | 30 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1998 | 67 | 0.010 |
Why?
|
Epinephrine | 1 | 1998 | 167 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 1440 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 1996 | 23 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1996 | 59 | 0.010 |
Why?
|
Collagen | 1 | 1998 | 433 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 2071 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1998 | 2657 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2002 | 3174 | 0.010 |
Why?
|